Avalyn Pharma Inc. (NasdaqGS: AVLN)
Health Care · Pharmaceuticals · US
$37.82
-3.66% today · +33.1% 1Y
Avalyn Pharma Inc. (NasdaqGS: AVLN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.74B and employs 50 people.
Over the last twelve months the share price has gained 33.1%, trading between 24.15 and 34.15.
AVLN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.74B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -78.19
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $34.15
- 52-week low
- $24.15
- Avg volume (3M)
- —
- Shares outstanding
- 44.33M
- Employees
- 50
- Next earnings
- —
About Avalyn Pharma Inc.
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
- ISIN
- US05348Y1055
- Founded
- 2011
- Listed since
- Apr 30, 2026
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,247.37 | -0.64% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $273.00 | +1.02% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.91 | -1.08% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.03 | -0.14% |
Figures last refreshed Aug 18, 2026.